Api iguramatimod

Formula

Seres Product Name: Ellamod

Seres alias: N [3 (Carboxamido) -4-Oxo-VI-phenoxy-4h-I-Benzopyran-VII-YL] Methanesulfonamide

Latina Product Name: iguratimod

CAS # 123663-49-0

Molecular formula: c17h14n2o6s

Molecular pondus: 374,3679

Specie et proprietates alba pulveris

Domesticis Registration Number API: Y20190021542

Iguratimod API est pro anti-RHEUMATICUS medicamento, Synovitis medicamento.

Iguratimod API (Active Pharmaceutical Ingredientia) est a novae parva-moltuulo immunomodulatory agente, quae est garnered significant operam in curatio autoimmune perturbationes, praecipue Rheumatoid (RHE). Developed ut morbus-modifying antirheumatic medicamento (Dmard), Iguratimod API exhibet unicum machinationes agendi, distinguendo ex conventional therapies. Hoc articulum explorat applications, vires, et challenges consociata cum Iguratimod API, extollit ejus crescente partes in modern pharmacoterapy.

Therapeutic Applications of iguratimod API

Rheumatoid arthritis (R.) Iguratimod API est praesertim indicavit ad ra administratione. Hoc inhibits pro-inflammatione cytokines, inter tnf-α et il-VI, cum suppressis Janus Kinase-signo transducer et activator de transcribenda (Jak-Stat) meatus. Volume iudiciis demonstrabo ad efficaciam in reducendo iuncturam inflammationem et tarditatem morbus progressionem.

Alia autoimmune perturbationes: emergentes studia suadeant potential applications of iguratimod API in systemica lupus erythematosus (Su) et Osteeothritis, propter suam anti-fibrotic et cartilaginem, tutela proprietatibus.

Compositum Lorem: Iguratimod API est magis solebat latere methotrexate aut biologics, enhancing medicinalis eventus in refractória Ra casibus.

Commoda Iguratimod API

Dual mechanism agendi: dissimilis traditional DMards, Igurimod API combines immunomoduli cum recta inhibitionis Osteoclasogenesis, addressing et inflammatio et os exesa.

Improved Safety Profile: comparari Corticosteroids vel non-steroidal anti-inflammatory medicamentis (nsaids), Iguratimod API exhibet paucioribus gastrointestinal et cardiovascular latus effectus.

Oral Administration: ut est viva bioavailable API, Iguratimod praebet commodum in injectable biologics, improving patientes estote obsequio.

Cost-efficaciam: Iguratimod API est magis amet quam biologic agentibus, faciens is obvius in resource-limited occasus.

Limitations et challenges

Moram impetu agendi: et effectus ex effectis Iguratimod API potest accipere 4-8 weeks ad manifestandum, limitando suum utilitatem in acuta flare-ups.

Hepatotoxicity metus: elevatum iecoris enzymes fuisse relatum in quibusdam aegris, necessitating iusto vigilantia.

Limited Global Approbatio: Dum Iguratimod API probatus est in Japan et Sina, adoptionem manet restricted in Western fora ex debitum ad insufficiens diu terminus salutem data.

Medicamento Interationes: Co-Administration cum fortis Cyp3a4 induers aut inhibitors ut alter Iguratimod API scriptor pharmacokinetics, requiring dose referendo.

Futurum prospectus

Ongoing Research Aims ad Expand Applications of Iguratimod API, comprehendo eius potential in Covi-XIX-related cytokine procellas et neurodegenerative morbo. Ceterum, formula innovations, ut Nanoparticle-fundatur Delivery Systems, potuit augendae eius bioavailability et targeting efficientiam.

Conclusio

Iguratimod API represents promittens therapeutica agente cum multifaceted applications in autoimmune morbo. Et unicum machinationes, oris bioavailability, et sumptus-efficaciam situm illud ut valuable alternative ad conventional therapies. Tamen, challenges ut moratus efficaciam et hepatotoxicity underscore opus vigilanti patientes estote administratione. Sicut orci quod crescit, Iguratimod API Maii solidatur ejus partes in global RHEUMATOLOGY usu, provisum suam salutem et versatility sunt adhuc convalidatur.